Dihydroergotoxine

• 产品号: DB01287
• CAS号: 11032-41-0
• 分子式: C34H41N5O8S
• 分子量: 679.78304

产品别名

• 标题: Dihydroergotoxine
• IUPAC标准名: (4R,7R)-N-[(1S,2S,4R,7S)-7-benzyl-2-hydroxy-4-methyl-5,8-dioxo-3-oxa-6,9-diazatricyclo[7.3.0.0^{2,6}]dodecan-4-yl]-6-methyl-6,11-diazatetracyclo[7.6.1.0^{2,7}.0^{12,16}]hexadeca-1(16),9,12,14-tetraene-4-carboxamide; methanesulfonic acid
• IUPAC传统名: (4R,7R)-N-[(1S,2S,4R,7S)-7-benzyl-2-hydroxy-4-methyl-5,8-dioxo-3-oxa-6,9-diazatricyclo[7.3.0.0^{2,6}]dodecan-4-yl]-6-methyl-6,11-diazatetracyclo[7.6.1.0^{2,7}.0^{12,16}]hexadeca-1(16),9,12,14-tetraene-4-carboxamide mesylate

产品登记号

• PubChem SID: 46505136
• PubChem CID: 6420006
• CAS号: 11032-41-0

产品详细信息

详细说明 (English)

• Drug Groups: approved
• Description: Dihydroergotoxine is a cerebral vasodilator. Dihydroergotoxine is a mixture of three different ergotamantriones: dihydroergocornine, dihydroergocristine, and dihydroergocryptine. It has been proposed to be a neuroprotective agent. The mechanism of its therapeutic actions is not clear.
• Indication: For potential use in the treatment of Alzheimer's disease.
• Pharmacology: The drug may compensate for neurotransmitter deficits and can in different circumstances, compensate for hyperactivity in the same neurotransmitter pathways. The drug can counteract and prevent disturbances between monoaminergic and other transmitter systems in the CNS.